Advertisment

COVID-19 Vaccine BY Johnson & Johnson Showed 66 % Effective In Phase 3 Of Global Trial

Johnson & Johnson is going to file for emergency use authorisation from the US Food and Drug Administration in a week.  This will be the third company to seek EUA from the FDA for a coronavirus vaccine.

author-image
STP Reporter
New Update
COVID booster shots, COVID-19 Vaccine And Menstruation, Covishield booster shot, Bharat Biotech Pune plant, COVID vaccination in diabetes, covid-19 vaccines in india, Shouldn’t Teachers Get COVID Vaccine, , COVID vaccination mandatory, Johnson showed 66 per cent effective ,Covaxin Effectiveness, Pregnant women COVID-19 vaccine, first vaccination drive January 16


Advertisment
Johnson showed 66 per cent effective: Johnson & Johnson's COVID-19 vaccine was shown to be 66% effective in preventing moderate and severe symptoms of the disease in Phase 3 trial, and 85% efficacy against severe disease, the company announced Friday.

The company also said that the vaccine was 72% effective against moderate and severe disease in the US.

The Pfizer/BioNTech and Moderna vaccines which are already out in the market are 95% effective but according to experts Johnson & Johnson vaccine will still be useful against the coronavirus in the United States and the world. 

"Among all participants from different geographies and including those infected with an emerging viral variant, Janssen's COVID-19 vaccine candidate was 66% effective overall at preventing the combined endpoints of moderate and severe COVID-19, 28 days after vaccination. The onset of protection was observed as early as day 14," the company said in a statement.

"The level of protection against moderate and severe COVID-19 infection was 72% in the US, 66% in Latin America and 57% in South Africa, 28 days post-vaccination."

Dr. Mathai Mammen, global head of research and development at Johnson & Johnson said, "We're 85% effective at preventing severe disease, which we define as the disease that makes you feel particularly sick at home, or may go to the hospital, or worse". 

Advertisment

"And we are right now completely protective, it would appear 100% protective, against disease that actually does make you go to the hospital, we're 100% protective against death."

The company said that the results have been concluded after taking people of all age groups around the world into account. 

Johnson & Johnson is going to file for emergency use authorisation from the US Food and Drug Administration in a week.  This will be the third company to seek EUA from the FDA for a coronavirus vaccine.  Moderna and by Pfizer/BioNTech were authorized in December and are already been given to people in America. 

Unlike the others, this vaccine will be effective in single-dose and it doesn't need to be stored in a freezer like Pfizer and Moderna. It can be stored in the refrigerator at a temperature of 36 and 46 degrees Fahrenheit for three months.  

COVID-19 vaccine Johnsons&Johnson
Advertisment